ABT vs CDNA

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ABT's RSI Indicator exited the oversold zone, 16 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 43%.

The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on ABT as a result. In 46 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 53%.

The Moving Average Convergence Divergence (MACD) for ABT just turned positive on October 09, 2026. Looking at past instances where ABT's MACD turned positive, the stock continued to rise in 25 of 54 cases over the following month. The odds of a continued upward trend are 46%.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The 10-day moving average for ABT crossed bearishly below the 50-day moving average on September 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 5 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 42%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.

ABT broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ABT entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. ABT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 68 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.469) is normal, around the industry mean (2.979). P/E Ratio (33.048) is within average values for comparable stocks, (2.590). Projected Growth (PEG Ratio) (1.853) is also within normal values, averaging (11.052). Dividend Yield (0.025) settles around the average of (0.009) among similar stocks. P/S Ratio (3.836) is also within normal values, averaging (40.124).

The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 58 cases where CDNA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on CDNA as a result. In 83 of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.

Following a +8.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where CDNA advanced for three days, in 238 of 288 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

Bearish Trend Analysis

The 10-day RSI Indicator for CDNA moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In 26 of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at 79%.

The Moving Average Convergence Divergence Histogram (MACD) for CDNA turned negative on October 08, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 36 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CDNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

CDNA broke above its upper Bollinger Band on September 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. CDNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 34 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 95 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CDNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.

The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.412) is normal, around the industry mean (64.051). P/E Ratio (32.037) is within average values for comparable stocks, (1.569). CDNA's Projected Growth (PEG Ratio) (48.410) is very high in comparison to the industry average of (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (6.146) is also within normal values, averaging (9.775).